Iron overload in sickle cell disease

Advances in Hematology

Volumn 2010, Issue , 2010, Pages

  Little, Jane A ^a   Raghupathy, Radha ^a   Manwani, Deepa ^a  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DEFERASIROX; DEFERIPRONE; DEFEROXAMINE; IRON; POLYMERIZED HEMOGLOBIN;

ACUTE CHEST SYNDROME; BLOOD TRANSFUSION; CHELATION THERAPY; DRUG EFFICACY; FERRITIN BLOOD LEVEL; GASTROINTESTINAL TOXICITY; GROWTH RETARDATION; HEADACHE; HUMAN; IRON METABOLISM; IRON OVERLOAD; NEPHROTOXICITY; PERCEPTION DEAFNESS; PRIORITY JOURNAL; RASH; RETINA INJURY; REVIEW; SICKLE CELL ANEMIA; SPLENECTOMY; STROKE; TREATMENT INDICATION;

EID: 77954585174     PISSN: 16879104     EISSN: 16879112     Source Type: Journal    
DOI: 10.1155/2010/272940     Document Type: Review

References (93)

1. Walter P. B., Harmatz P., Vichinsky E., Iron metabolism and iron chelation in sickle cell disease Acta Haematologica 2009 122 2-3 174 183
2. Dubach R., Moore C. V., Callender S., Studies in iron transportation and metabolism. IX. The excretion of iron as measured by the isotope technique The Journal of Laboratory and Clinical Medicine 1955 45 4 599 615
3. Andrews N. C., Iron homeostasis: insights from genetics and animal models Nature Reviews Genetics 2000 1 3 208 217
4. Fleming R. E., Bacon B. R., Orchestration of iron homeostasis New England Journal of Medicine 2005 352 17 1741 1744
5. Hentze M. W., Muckenthaler M. U., Andrews N. C., Balancing acts: molecular control of mammalian iron metabolism Cell 2004 117 3 285 297
6. Nemeth E., Iron regulation and erythropoiesis Current Opinion in Hematology 2008 15 3 169 175
7. Nicolas G., Chauvet C., Viatte L., The gene encoding the iron regulatory peptide hepcidin is regulated by anemia, hypoxia, and inflammation Journal of Clinical Investigation 2002 110 7 1037 1044
8. Babitt J. L., Huang F. W., Wrighting D. M., Bone morphogenetic protein signaling by hemojuvelin regulates hepcidin expression Nature Genetics 2006 38 5 531 539
9. Du X., She E., Gelbart T., The serine protease TMPRSS6 is required to sense iron deficiency Science 2008 320 5879 1088 1092
10. Shayeghi M., Latunde-Dada G. O., Oakhill J. S., Identification of an intestinal heme transporter Cell 2005 122 5 789 801
11. Raffin S. B., Woo C. H., Roost K. T., Intestinal absorption of hemoglobin iron heme cleavage by mucosal heme oxygenase Journal of Clinical Investigation 1974 54 6 1344 1352
12. Quigley J. G., Yang Z., Worthington M. T., Identification of a human heme exporter that is essential for erythropoiesis Cell 2004 118 6 757 766
13. Keel S. B., Doty R. T., Yang Z., A heme export protein is required for red blood cell differentiation and iron homeostasis Science 2008 319 5864 825 828
14. Russell M. O., Goldberg H. I., Hodson A., Effect of transfusion therapy on arteriographic abnormalities and on recurrence of stroke in sickle cell disease Blood 1984 63 1 162 169
15. Telen M. J., Principles and problems of transfusion in sickle cell disease Seminars in Hematology 2001 38 4 315 323
16. Ballas S. K., Sickle cell disease: current clinical management Seminars in Hematology 2001 38 4 307 314
17. Pegelow C. H., Adams R. J., McKie V., Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions Journal of Pediatrics 1995 126 6 896 899
18. Adams R. J., Mckie V. C., Hsu L., Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial Doppler ultrasonography New England Journal of Medicine 1998 339 1 5 11
19. Adams R. J., Brambilla D., Discontinuing prophylactic transfusions used to prevent stroke in sickle cell disease New England Journal of Medicine 2005 353 26 2769 2778
20. Swerdlow P. S., Red cell exchange in sickle cell disease Hematology 2006 48 53
21. Emre U., Miller S. T., Gutierez M., Steiner P., Rao S. P., Rao M., Effect of transfusion in acute chest syndrome of sickle cell disease Journal of Pediatrics 1995 127 6 901 904
22. Vichinsky E. P., Neumayr L. D., Earles A. N., Causes and outcomes of the acute chest syndrome in sickle cell disease New England Journal of Medicine 2000 342 25 1855 1865
23. Miller S. T., Wright E., Abboud M., Impact of chronic transfusion on incidence of pain and acute chest syndrome during the Stroke Prevention Trial (STOP) in sickle-cell anemia Journal of Pediatrics 2001 139 6 785 789
24. Styles L. A., Abboud M., Larkin S., Lo M., Kuypers F. A., Transfusion prevents acute chest syndrome predicted by elevated secretory phospholipase A2 British Journal of Haematology 2007 136 2 343 344
25. Koshy M., Burd L., Wallace D., Moawad A., Baron J., Prophylactic red-cell transfusions in pregnant patients with sickle cell disease. A randomized cooperative study New England Journal of Medicine 1988 319 22 1447 1452
26. Vichinsky E. P., Haberkern C. M., Neumayr L., A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease New England Journal of Medicine 1995 333 4 206 213
27. Koshy M., Weiner S. J., Miller S. T., Surgery and anesthesia in sickle cell disease Blood 1995 86 10 3676 3684
28. Ware R., Filston H. C., Schultz W. H., Kinney T. R., Elective cholecystectomy in children with sickle hemoglobinopathies. Successful outcome using a preoperative transfusion regimen Annals of Surgery 1988 208 1 17 22
29. Fung E. B., Harmatz P., Milet M., Morbidity and mortality in chronically transfused subjects with Thalassemia and Sickle Cell Disease: a report from the multi-center study of iron overload American Journal of Hematology 2007 82 4 255 265
30. Ballas S. K., Iron overload is a determinant of morbidity and mortality in adult patients with sickle cell disease Seminars in Hematology 2001 38 1, supplement 1 30 36
31. Fung E. B., Harmatz P. R., Milet M., Disparity in the management of iron overload between patients with sickle cell disease and thalassemia who received transfusions Transfusion 2008 48 9 1971 1980
32. Andrews N. C., Disorders of iron metabolism New England Journal of Medicine 1999 341 26 1986 1995
33. Wang W. C., Ahmed N., Hanna M., Non-transferrin-bound iron in long-term transfusion in children with congenital anemias Journal of Pediatrics 1986 108 4 552 557
34. Esposito B. P., Breuer W., Sirankapracha P., Pootrakul P., Hershko C., Cabantchik Z. I., Labile plasma iron in iron overload: redox activity and susceptibility to chelation Blood 2003 102 7 2670 2677
35. Hershko C., Graham G., Bates G. W., Rachmilewitz E. A., Non-specific serum iron in thalassaemia: an abnormal serum iron fraction of potential toxicity British Journal of Haematology 1978 40 2 255 263
36. Breuer W., Hershko C., Cabantchik Z. I., The importance of non-transferrin bound iron in disorders of iron metabolism Transfusion Science 2000 23 3 185 192
37. Link G., Pinson A., Hershko C., Heart cells in culture: a model of myocardial iron overload and chelation The Journal of Laboratory and Clinical Medicine 1985 106 2 147 153
38. Cabantchik Z. I., Breuer W., Zanninelli G., Cianciulli P., LPI-labile plasma iron in iron overload Best Practice and Research: Clinical Haematology 2005 18 2 277 287
39. Goddard J. G., Sweeney G. D., Ferric nitrilotriacetate: a potent stimulant of in vivo lipid peroxidation in mice Biochemical Pharmacology 1983 32 24 3879 3882
40. Hershko C., Link G., Konijn A. M., Cabantchik Z. I., Objectives and mechanism of iron chelation therapy Annals of the New York Academy of Sciences 2005 1054 124 135
41. Olivieri N. F., Brittenham G. M., Iron-chelating therapy and the treatment of thalassemia Blood 1997 89 3 739 761
42. Wood J. C., Tyszka J. M., Carson S., Nelson M. D., Coates T. D., Myocardial iron loading in transfusion-dependent thalassemia and sickle cell disease Blood 2004 103 5 1934 1936
43. Vichinsky E., Butensky E., Fung E., Comparison of organ dysfunction in transfused patients with SCD or thalassemia American Journal of Hematology 2005 80 1 70 74
44. Walter P. B., Fung E. B., Killilea D. W., Oxidative stress and inflammation in iron-overloaded patients with -thalassaemia or sickle cell disease British Journal of Haematology 2006 135 2 254 263
45. Koren A., Fink D., Admoni O., Tennenbaum-Rakover Y., Levin C., Non-transferrin bound labile plasma iron and iron overload in sickle cell disease: a comparative study between sickle cell disease and thalassemic patients European Journal of Haematology 2010 84 1 72 78
46. Jeng M. R., Adams-Graves P., Howard T. A., Whorton M. R., Li C.-S., Ware R. E., Identification of hemochromatosis gene polymorphisms in chronically transfused patients with sickle cell diseases American Journal of Hematology 2003 74 4 243 248
47. Gordeuk V. R., Boyd R. D., Brittenham G. M., Dietary iron overload persists in rural sub-Saharan Africa Lancet 1986 1 8493 1310 1313
48. Wurapa R. K., Gordeuk V. R., Brittenham G. M., Khiyami A., Schechter G. P., Edwards C. Q., Primary iron overload in African Americans American Journal of Medicine 1996 101 1 9 18
49. Hebbel R. P., Osarogiagbon R., Kaul D., The endothelial biology of sickle cell disease: inflammation and a chronic vasculopathy Microcirculation 2004 11 2 129 151
50. Jison M. L., Munson P. J., Barb J. J., Blood mononuclear cell gene expression profiles characterize the oxidant, hemolytic, and inflammatory stress of sickle cell disease Blood 2004 104 1 270 280
51. Belcher J. D., Marker P. H., Weber J. P., Hebbel R. P., Vercellotti G. M., Activated monocytes in sickle cell disease: potential role in the activation of vascular endothelium and vaso-occlusion Blood 2000 96 7 2451 2459
52. Ezeh C., Ugochukwu C. C., Weinstein J., Okpala I., Hepcidin, haemoglobin and ferritin levels in sickle cell anaemia European Journal of Haematology 2005 74 1 86 88
53. Kroot J. J. C., Laarakkers C. M. M., Kemna E. H. J. M., Biemond B. J., Swinkels D. W., Regulation of serum hepcidin levels in sickle cell disease Haematologica 2009 94 6 885 887
54. Vichinsky E., Kleman K., Embury S., Lubin B., The diagnosis of iron deficiency anemia in sickle cell disease Blood 1981 58 5 963 968
55. Jenkins Z. A., Hagar W., Bowlus C. L., Iron homeostasis during transfusional iron overload in -thalassemia and sickle cell disease: changes in iron regulatory protein, hepcidin, and ferritin expression Pediatric Hematology and Oncology 2007 24 4 237 243
56. Papanikolaou G., Tzilianos M., Christakis J. I., Hepcidin in iron overload disorders Blood 2005 105 10 4103 4105
57. Origa R., Galanello R., Ganz T., Liver iron concentrations and urinary hepcidin in -thalassemia Haematologica 2007 92 5 583 588
58. Gardenghi S., Marongiu M. F., Ramos P., Ineffective erythropoiesis in -thalassemia is characterized by increased iron absorption mediated by down-regulation of hepcidin and up-regulation of ferroportin Blood 2007 109 11 5027 5035
59. Kearney S. L., Nemeth E., Neufeld E. J., Urinary hepcidin in congenital chronic anemias Pediatric Blood and Cancer 2007 48 1 57 63
60. Tanno T., Bhanu N. V., Oneal P. A., High levels of GDF15 in thalassemia suppress expression of the iron regulatory protein hepcidin Nature Medicine 2007 13 9 1096 1101
61. Tanno T., Porayette P., Sripichai O., Identification of TWSG1 as a second novel erythroid regulator of hepcidin expression in murine and human cells Blood 2009 114 1 181 186
62. Angelucci E., Brittenham G. M., McLaren C. E., Hepatic iron concentration and total body iron stores in thalassemia major New England Journal of Medicine 2000 343 5 327 331
63. Bassett M. L., Halliday J. W., Powell L. W., Value of hepatic iron measurements in early hemochromatosis and determination of the critical iron level associated with fibrosis Hepatology 1986 6 1 24 29
64. Angelucci E., Baronciani D., Lucarelli G., Needle liver biopsy in thalassaemia: analyses of diagnostic accuracy and safety in 1184 consecutive biopsies British Journal of Haematology 1995 89 4 757 761
65. Telfer P. T., Prestcott E., Holden S., Walker M., Hoffbrand A. V., Wonke B., Hepatic iron concentration combined with long-term monitoring of serum ferritin to predict complications of iron overload in thalassaemia major British Journal of Haematology 2000 110 4 971 977
66. Brown K., Subramony C., May W., Hepatic iron overload in children with sickle cell anemia on chronic transfusion therapy Journal of Pediatric Hematology/Oncology 2009 31 5 309 312
67. Harmatz P., Butensky E., Quirolo K., Severity of iron overload in patients with sickle cell disease receiving chronic red blood cell transfusion therapy Blood 2000 96 1 76 79
68. Adamkiewicz T. V., Abboud M. R., Paley C., Serum ferritin level changes in children with sickle cell disease on chronic blood transfusion are nonlinear and are associated with iron load and liver injury Blood 2009 114 21 4632 4638
69. Brittenham G. M., Farrell D. E., Harris J. W., Magnetic-susceptibility measurement of human iron stores New England Journal of Medicine 1982 307 27 1671 1675
70. Voskaridou E., Douskou M., Terpos E., Magnetic resonance imaging in the evaluation of iron overload in patients with beta thalassaemia and sickle cell disease British Journal of Haematology 2004 126 5 736 742
71. Voskaridou E., Douskou M., Terpos E., Deferiprone as an oral iron chelator in sickle cell disease Annals of Hematology 2005 84 7 434 440
72. Anderson L. J., Holden S., Davis B., Cardiovascular T2-star (T 2 ) magnetic resonance for the early diagnosis of myocardial iron overload European Heart Journal 2001 22 23 2171 2179
73. Wood J. C., Enriquez C., Ghugre N., MRI R2 and R 2 mapping accurately estimates hepatic iron concentration in transfusion-dependent thalassemia and sickle cell disease patients Blood 2005 106 4 1460 1465
74. Kim H. C., Dugan N. P., Silber J. H., Erythrocytapheresis therapy to reduce iron overload in chronically transfused patients with sickle cell disease Blood 1994 83 4 1136 1142
75. Wagner S. C., Eschelman D. J., Gonsalves C. F., Bonn J., Sullivan K. L., Infectious complications of implantable venous access devices in patients with sickle cell disease Journal of Vascular and Interventional Radiology 2004 15 4 375 378
76. McCready C. E., Doughty H. A., Pearson T. C., Experience with the Port-A-Cath in sickle cell disease Clinical and Laboratory Haematology 1996 18 2 79 82
77. Aygun B., Padmanabhan S., Paley C., Chandrasekaran V., Clinical significance of RBC alloantibodies and autoantibodies in sickle cell patients who received transfusions Transfusion 2002 42 1 37 43
78. Collins A. F., Goncalves-Dias C., Haddad S., Comparison of a transfusion preparation of newly formed red cells and standard washed red cell transfusions in patients with homozygous -thalassemia Transfusion 1994 34 6 517 520
79. Haricharan R. N., Roberts J. M., Morgan T. L., Splenectomy reduces packed red cell transfusion requirement in children with sickle cell disease Journal of Pediatric Surgery 2008 43 6 1052 1056
80. Pootrakul P., Breuer W., Sametband M., Sirankapracha P., Hershko C., Cabantchik Z. I., Labile plasma iron (LPI) as an indicator of chelatable plasma redox activity in iron-overloaded -thalassemia/HbE patients treated with an oral chelator Blood 2004 104 5 1504 1510
81. Risdon R. A., Barry M., Flynn D. M., Transfusional iron overload: the relationship between tissue iron concentration and hepatic fibrosis in thalassaemia Journal of Pathology 1975 116 2 83 95
82. Olivieri N. F., Progression of iron overload in sickle cell disease Seminars in Hematology 2001 38 1, supplement 1 57 62
83. Mahesh S., Ginzburg Y., Verma A., Iron overload in myelodysplastic syndromes Leukemia and Lymphoma 2008 49 3 427 438
84. Porter J. B., Practical management of iron overload British Journal of Haematology 2001 115 2 239 252
85. Brittenham G. M., Griffith P. M., Nienhuis A. W., Efficacy of deferoxamine in preventing complications of iron overload in patients with thalassemia major New England Journal of Medicine 1994 331 9 567 573
86. Olivieri N. F., Buncic J. R., Chew E., Visual and auditory neurotoxicity in patients receiving subcutaneous deferoxamine infusions New England Journal of Medicine 1986 314 14 869 873
87. Kidson-Gerber G., Lindeman R., Adherence to desferrioxamine and deferiprone and the impact of deferiprone co-prescription in thalassaemia major patients. Does the addition of deferiprone improve adherence? British Journal of Haematology 2008 142 4 679 680
88. Cappellini M. D., Overcoming the challenge of patient compliance with iron chelation therapy Seminars in Hematology 2005 42 2, supplement 1 S19 S21
89. Franchini M., Gandini G., Veneri D., Aprili G., Safety and efficacy of subcutaneous bolus injection of deferoxamine in adult patients with iron overload: an update Blood 2004 103 2 747 748
90. Yarali N., Figin T., Duru F., Subcutaneous bolus injection of deferoxamine is an alternative method to subcutaneous continuous infusion Journal of Pediatric Hematology/Oncology 2006 28 1 11 16
91. Vichinsky E., Onyekwere O., Porter J., A randomised comparison of deferasirox versus deferoxamine for the treatment of transfusional iron overload in sickle cell disease British Journal of Haematology 2007 136 3 501 508
92. Cohen A. R., Galanello R., Piga A., De Sanctis V., Tricta F., Safety and effectiveness of long-term therapy with the oral iron chelator deferiprone Blood 2003 102 5 1583 1587
93. Roberts D. J., Brunskill S. J., Doree C., Williams S., Howard J., Hyde C. J., Oral deferiprone for iron chelation in people with thalassaemia Cochrane Database of Systematic Reviews 2007 3